Novartis AG's Rydapt (midostaurin) was approved for two different indications and will carry two different prices, one that appears more in line with typical targeted oncology medicines and the other that is in line with drugs for ultra-rare diseases.
In both instances, Rydapt appears to be an important new treatment option. The drug was approved by FDA April 28...